Robert G Deeter

1.6k total citations · 1 hit paper
31 papers, 1.2k citations indexed

About

Robert G Deeter is a scholar working on Oncology, Epidemiology and Pharmacology. According to data from OpenAlex, Robert G Deeter has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Epidemiology and 6 papers in Pharmacology. Recurrent topics in Robert G Deeter's work include Neutropenia and Cancer Infections (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (5 papers). Robert G Deeter is often cited by papers focused on Neutropenia and Cancer Infections (6 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (5 papers). Robert G Deeter collaborates with scholars based in United States, Germany and United Kingdom. Robert G Deeter's co-authors include Allen Lee Cohn, Seta Shahin, John L. Marshall, David McCollum, Edith P. Mitchell, Christopher Hagenstad, Philip J. Stella, Tarek Chidiac, J. Randolph Hecht and Rafael G. Amado and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Robert G Deeter

31 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 644 citations J. Randolph Hecht, Edith P. Mitchell et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert G Deeter United States	14	812	325	194	164	157	31	1.2k
Qiwen Fang China	11	385 0.5×	126 0.4×	164 0.8×	93 0.6×	357 2.3×	34	1.2k
Chengli Shen United States	22	345 0.4×	195 0.6×	340 1.8×	61 0.4×	413 2.6×	77	1.4k
Neal Bhutiani United States	20	452 0.6×	196 0.6×	96 0.5×	88 0.5×	156 1.0×	99	1.3k
Jennifer Trofe United States	19	1.3k 1.6×	131 0.4×	61 0.3×	67 0.4×	308 2.0×	33	1.9k
Maureen Reiner United States	22	707 0.9×	254 0.8×	54 0.3×	295 1.8×	153 1.0×	51	1.4k
Renaud Snanoudj France	28	233 0.3×	318 1.0×	74 0.4×	110 0.7×	413 2.6×	84	2.4k
Ian R. Hardie Australia	19	615 0.8×	242 0.7×	52 0.3×	61 0.4×	656 4.2×	57	1.8k
Lutz Renders Germany	22	188 0.2×	212 0.7×	60 0.3×	39 0.2×	200 1.3×	94	1.5k
Pinit Kullavanijaya Thailand	24	685 0.8×	698 2.1×	457 2.4×	140 0.9×	371 2.4×	131	1.9k
H.-U. Meier-Kriesche United States	20	316 0.4×	221 0.7×	193 1.0×	45 0.3×	390 2.5×	43	2.3k

Countries citing papers authored by Robert G Deeter

Since Specialization

Citations

This map shows the geographic impact of Robert G Deeter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G Deeter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G Deeter more than expected).

Fields of papers citing papers by Robert G Deeter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert G Deeter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G Deeter. The network helps show where Robert G Deeter may publish in the future.

Co-authorship network of co-authors of Robert G Deeter

This figure shows the co-authorship network connecting the top 25 collaborators of Robert G Deeter. A scholar is included among the top collaborators of Robert G Deeter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G Deeter. Robert G Deeter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danese, Mark D., Robert I. Griffiths, Michelle Gleeson, et al.. (2016). Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leukemia & lymphoma. 58(5). 1094–1104. 26 indexed citations

Weycker, Derek, et al.. (2013). Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Services Research. 13(1). 60–60. 43 indexed citations

Naeim, Arash, Henry J. Henk, Laura Becker, et al.. (2013). Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 13(1). 11–11. 70 indexed citations

Pawaskar, Manjiri, Sudeep Karve, Tapashi Dalvi, Keith L. Davis, & Robert G Deeter. (2013). Health care utilization and costs among HER2-negative, HR-positive, elderly women with metastatic breast cancer in the United States.. Journal of Clinical Oncology. 31(15_suppl). e11571–e11571. 3 indexed citations

Karve, Sudeep, Manjiri Pawaskar, Keith L. Davis, Tapashi Dalvi, & Robert G Deeter. (2013). Treatment patterns and survival in elderly women with HER2-negative, hormone receptor positive metastatic breast cancer: Analysis of the SEER-Medicare database.. Journal of Clinical Oncology. 31(15_suppl). e11570–e11570. 1 indexed citations

Henk, Henry J., Laura Becker, Hiangkiat Tan, et al.. (2012). Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. Journal of Medical Economics. 16(1). 160–168. 15 indexed citations

Deeter, Robert G, et al.. (2011). Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Experimental and Therapeutic Medicine. 2(5). 859–866. 73 indexed citations

Naeim, Arash, Henry J. Henk, Laura Becker, et al.. (2010). Pegfilgrastim Use Associated with Lower Risk of Hospitalization Than Filgrastim Use: A Retrospective US Claims Analysis.. Blood. 116(21). 3801–3801. 2 indexed citations

Hecht, J. Randolph, Edith P. Mitchell, Tarek Chidiac, et al.. (2008). A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology. 27(5). 672–680. 644 indexed citations breakdown →

10.

Andrews, William W., Debora F. Kimberlin, Richard J. Whitley, et al.. (2006). Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. American Journal of Obstetrics and Gynecology. 194(3). 774–781. 59 indexed citations

11.

Lerner, A. Martin, Howard J. Dworkin, James T. Fitzgerald, et al.. (2005). Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome.. PubMed. 18(4). 417–24. 10 indexed citations

12.

Beqaj, Safedin, Robert G Deeter, Howard J. Dworkin, et al.. (2002). A six-month trial of valacyclovir in the Epstein-Barr virus subsetof chronic fatigue syndrome: Improvement in left ventricularfunction. Drugs of today. 38(8). 549–549. 14 indexed citations

13.

Fish, Douglas N., et al.. (2002). Pharmacokinetics and Safety of Valaciclovir in Children with Epstein-Barr Virus Illness. Drugs in R&D. 3(6). 365–373. 9 indexed citations

14.

Haddad, Joseph, Lisa Saiman, Pablo Gabriel, et al.. (2000). Nonsusceptible Streptococcus pneumoniae in children with chronic otitis media with effusion and recurrent otitis media undergoing ventilating tube placement. The Pediatric Infectious Disease Journal. 19(5). 432–437. 9 indexed citations

15.

Dhaliwal, Deepinder K., Eric G. Romanowski, Kathleen A. Yates, et al.. (1999). Valacyclovir Inhibits Recovery of Ocular HSV-1 After Experimental Reactivation by Excimer Laser Keratectomy. Cornea. 18(6). 693–693. 12 indexed citations

16.

Fish, Douglas N., et al.. (1999). Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. American Journal of Health-System Pharmacy. 56(19). 1957–1960. 17 indexed citations

17.

Deeter, Robert G, Dave Kalman, Mark P. Rogan, & Shein‐Chung Chow. (1993). Therapy for pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci: a meta-analysis comparing the efficacy and safety of cefadroxil monohydrate versus oral penicillin V.. PubMed. 14(5). 740–54. 14 indexed citations

18.

Deeter, Robert G, et al.. (1991). Respiratory Tract Penetration of Quinolone Antimicrobials: A Case in Study. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 11(1). 38–49. 12 indexed citations

19.

Deeter, Robert G, et al.. (1990). Treatment of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.. PubMed. 9(2). 102–18. 9 indexed citations

20.

Deeter, Robert G, et al.. (1989). Comparison of Aminoglycoside Clearance and Calculated Serum Creatinine Clearances. Therapeutic Drug Monitoring. 11(2). 155–161. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact